BSEResult3 Nov 2026 · 3 Nov 2026, 07:23 pm

Unaudited Financial Results for the Quarter and half year ended as on September 30, 2026

Evonile Pharma Ltd · 500672

✦ AI SummaryResults

Evonile Pharma Ltd has submitted its unaudited financial results for the quarter and half year ended September 30, 2026, with total financial indebtedness of Rs. 800 crore, including short-term and long-term debt. The company has disclosed related party transactions with its subsidiaries and has not reported any defaults on loans or debt securities.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern3/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Evonile Pharma Ltd - 500672 - Unaudited Financial Results For The Quarter And Half Year Ended As On September 30, 2026.

Attachments (1)

📄

a57b4a67-e392-47fb-a2be-568e17eb6fb3.pdf

pdf

Download →
View document text
Evonile Pharma Limited (formerly known as Novartis India Limited) November 03, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub.: Integrated Filing (Financial) for the Quarter and half year ended September 30, 2026. Dear Sir/ Madam, Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we hereby submit the Unaudited Financial Statements for the quarter and half year ended September 30, 2026, together with the Limited Review Report thereon (Annexures I and II), along with the other disclosures forming part of the Integrated Filing (Financial) for the quarter and half year ended September 30, 2026. This is for your information and records. Thanking You, For Evonile Pharma Limited (Formerly known as Novartis India Limited) Chandni Maru Company Secretary & Compliance Officer A60291 Encl: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Integrated Filing (Financial) for the quarter and half year ended September 30, 2026. B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: Not Applicable C. Disclosure of Outstanding Default on Loans and Debt Securities: - Not Applicable Sr Particulars Amount No. (INR) 1. Loans / revolving facilities like cash credit from banks / financial institutions A. Total amount outstanding as on date 800 B. Of the total amount outstanding, amount of default as Nil on date 2. Unlisted debt securities i.e. NCDs and NCRPS - A. Total amount outstanding as on date - B. Of the total amount outstanding, amount of default as - on date 3. Total financial indebtedness of the listed entity including 800 short-term and long-term debt D. Disclosure of Related Party Transactions (Applicable only for Half Yearly Filings (i.e. 02nd and 04th Quarter): Annexure-III E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable Only for Annual Filing i.e. 4th Quarter): Not Applicable Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Annexure III Value of the related Value Value party Value of of of transac transacti transac transa Type of tion as on tion ction In case amount related approv during during during are due to either Details of the counterparty party ed by the the the party as a result of transacti the reporting reportin reporti the transaction on audit period g ng commit QTD period period tee/ Sep'26 YTD YTD Board Sep'26 Jun'26 FY26 Relationshi p of the Openi counterpar QTD YTD YTD ng Closing Name Name ty with the Sep'26 Sep'26 Jun'26 balan balance listed entity or its subsidiary Novartis AG - Subsidiary Royalty - 1 Upto 29th July 48.76 1.43 9.42 7.99 10.92 -8.48 2026 Novartis Subsidiary NBS -2.23 Healthcare services 30.00 1.97 7.90 5.92 -2.23 2 Private Limited - Upto 29th July 2026 Novartis Subsidiary Business Healthcare support 66.00 20.06 34.67 14.61 -3.05 -25.51 3 Private Limited services Evonile - Upto 29th availed Pharma July 2026 Limited Novartis Subsidiary Promotio (Formely Healthcare nal and 12.10 0.74 2.86 2.13 0.81 0.79 known as 4 Private Limited marketin Novartis - Upto 29th g India July 2026 services Lim ited) Novartis Subsidiary ESO Healthcare services 41.00 0.42 6.97 6.55 3.05 0.45 5 Private Limited provided - Upto 29th July 2026 Subsidiary Employe Novartis e 5.00 0.35 0.35 - - -0.24 Healthcare balances 6 Private Limited transferr - Upto 29th ed – July 2026 payable Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Subsidiary Employe 0.00 Novartis e 5.00 2.85 2.85 - - Healthcare balances 7 Private Limited transferr - Upto 29th ed – July 2026 receivabl Novartis India Subsidiary Provident Limited fund 120.00 0.47 2.18 1.70 - - Employees' contributi Provident Fund on Novartis India Subsidiary Superann Limited uation 3.00 - - - - - Superannuatio contributi n Fund on Subsidiary Gratuity 0.00 Novartis India fund 23.00 - - - - 10 Limited contributi Gratuity fund Novartis Subsidiary Purchase - Pharma AG - of stock 3,000.0 97.80 526.57 428.77 293.3 -97.80 Upto 29th July in trade 0 2 2026 Novartis- Subsidiary ESOP / Mitarbeiterbet ESPP 10.00 - 0.06 0.06 -3.50 - eiligungsstiftu ng (MBS) - Upto 29th July 2026 To 3363.86 126.09 593.83 467.74 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com